Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer
S Demaria, N Kawashima, AM Yang, ML Devitt… - Clinical Cancer …, 2005 - AACR
S Demaria, N Kawashima, AM Yang, ML Devitt, JS Babb, JP Allison, SC Formenti
Clinical Cancer Research, 2005•AACRPurpose: Ionizing radiation therapy (RT) is an important component in the management of
breast cancer. Although the primary tumor can be successfully treated by surgery and RT,
metastatic breast cancer remains a therapeutic challenge. Here we tested the hypothesis
that the combination of RT to the primary tumor with CTLA-4 blockade can elicit antitumor
immunity inhibiting the metastases. Experimental Design: The poorly immunogenic
metastatic mouse mammary carcinoma 4T1 was used as a model. Mice were injected sc …
breast cancer. Although the primary tumor can be successfully treated by surgery and RT,
metastatic breast cancer remains a therapeutic challenge. Here we tested the hypothesis
that the combination of RT to the primary tumor with CTLA-4 blockade can elicit antitumor
immunity inhibiting the metastases. Experimental Design: The poorly immunogenic
metastatic mouse mammary carcinoma 4T1 was used as a model. Mice were injected sc …
Abstract
Purpose: Ionizing radiation therapy (RT) is an important component in the management of breast cancer. Although the primary tumor can be successfully treated by surgery and RT, metastatic breast cancer remains a therapeutic challenge. Here we tested the hypothesis that the combination of RT to the primary tumor with CTLA-4 blockade can elicit antitumor immunity inhibiting the metastases.
Experimental Design: The poorly immunogenic metastatic mouse mammary carcinoma 4T1 was used as a model. Mice were injected s.c. with 4T1 cells, and treatment was started 13 days later when the primary tumors measured 5 mm in average diameter. Mice were randomly assigned to four treatment groups receiving: (1) control IgG (IgG), (2) RT + IgG, (3) 9H10 monoclonal antibody against CTLA-4, (4) RT + 9H10. RT was delivered to the primary tumor by one or two fractions of 12 Gy. 9H10 and IgG were given i.p. thrice after RT.
Results: Consistent with the fact that 4T1 is poorly immunogenic, 9H10 alone did not have any effect on primary tumor growth or survival. RT was able to delay the growth of the primary irradiated tumor, but in the absence of 9H10 survival was similar to that of control mice. In contrast, mice treated with RT + 9H10 had a statistically significant survival advantage. The increased survival correlated with inhibition of lung metastases formation and required CD8+ but not CD4+ T cells.
Conclusions: The combination of local RT with CTLA-4 blockade is a promising new immunotherapeutic strategy against poorly immunogenic metastatic cancers.
AACR